📊 FBLG Key Takeaways
Is FibroBiologics, Inc. (FBLG) a Good Investment?
FibroBiologics is a pre-revenue biopharmaceutical company burning cash at an unsustainable rate with -$16.4M operating cash flow against minimal assets of $9.6M. With only $4.9M in cash and negative operating margins, the company has approximately 3 quarters of runway before potential insolvency without additional funding or major operational changes.
FibroBiologics appears to be a pre-revenue biotech with no demonstrated commercial traction and deeply negative operating economics. The balance sheet still shows positive equity and solid near-term current liquidity, but cash burn is far above cash on hand, implying a strong dependence on external financing. Fundamentally, this is a high-risk profile with weak profitability trends, poor cash flow quality, and limited financial durability absent new capital or clinical/commercial progress.
Why Buy FibroBiologics, Inc. Stock? FBLG Key Strengths
- Strong current ratio of 3.61x indicates adequate short-term liquidity position
- Manageable debt-to-equity ratio of 0.70x suggests conservative capital structure
- 4 Form 4 insider filings suggest active insider engagement with company direction
- Current and quick ratios of 3.61x indicate acceptable near-term balance sheet liquidity
- Positive stockholders' equity of $6.16M means the company is not yet balance-sheet insolvent
- Debt/equity of 0.70x is not extreme for a development-stage company despite ongoing losses
FBLG Stock Risks: FibroBiologics, Inc. Investment Risks
- Pre-revenue stage with no commercial products generating income creates existential risk
- Severe cash burn rate of -$16.4M annually against only $4.9M cash balance indicates critical runway concerns
- Negative ROE of -302.9% and ROA of -193.8% demonstrate value destruction with each operating period
- Worsening net losses with -67.1% YoY decline in net income shows deteriorating financial position
- R&D-heavy cost structure without offsetting revenue creates unsustainable business model in current form
- No revenue base or gross profit makes the business entirely dependent on future development success rather than current operations
- Operating cash flow of -$16.39M versus only $4.89M of cash suggests limited runway and likely future capital raises
- Severely negative ROE, ROA, operating income, and interest coverage indicate weak financial health and poor earnings quality
Key Metrics to Watch
- Cash burn rate and runway to profitability or next funding event
- Revenue generation timeline and clinical trial progress milestones
- Quarterly operating cash flow trends for signs of cost reduction
- Debt covenant compliance and refinancing requirements
- Insider buying/selling patterns indicating confidence levels
- Cash runway relative to quarterly operating cash burn
- Revenue generation or clinical milestones that can support a path to sustainable operating improvement
FibroBiologics, Inc. (FBLG) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.61x current ratio provides a solid financial cushion.
FBLG Profit Margin, ROE & Profitability Analysis
FBLG vs Healthcare Sector: How FibroBiologics, Inc. Compares
How FibroBiologics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FibroBiologics, Inc. Stock Overvalued? FBLG Valuation Analysis 2026
Based on fundamental analysis, FibroBiologics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FibroBiologics, Inc. Balance Sheet: FBLG Debt, Cash & Liquidity
FBLG Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: FibroBiologics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.34 indicates the company is currently unprofitable.
FBLG Revenue Growth, EPS Growth & YoY Performance
FibroBiologics, Inc. Dividends, Buybacks & Capital Allocation
FBLG SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for FibroBiologics, Inc. (CIK: 0001958777)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FBLG
What is the AI rating for FBLG?
FibroBiologics, Inc. (FBLG) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FBLG's key strengths?
Claude: Strong current ratio of 3.61x indicates adequate short-term liquidity position. Manageable debt-to-equity ratio of 0.70x suggests conservative capital structure. ChatGPT: Current and quick ratios of 3.61x indicate acceptable near-term balance sheet liquidity. Positive stockholders' equity of $6.16M means the company is not yet balance-sheet insolvent.
What are the risks of investing in FBLG?
Claude: Pre-revenue stage with no commercial products generating income creates existential risk. Severe cash burn rate of -$16.4M annually against only $4.9M cash balance indicates critical runway concerns. ChatGPT: No revenue base or gross profit makes the business entirely dependent on future development success rather than current operations. Operating cash flow of -$16.39M versus only $4.89M of cash suggests limited runway and likely future capital raises.
What is FBLG's revenue and growth?
FibroBiologics, Inc. reported revenue of N/A.
Does FBLG pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
Where can I find FBLG SEC filings?
Official SEC filings for FibroBiologics, Inc. (CIK: 0001958777) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FBLG's EPS?
FibroBiologics, Inc. has a diluted EPS of $-0.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FBLG a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, FibroBiologics, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FBLG stock overvalued or undervalued?
Valuation metrics for FBLG: ROE of -302.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FBLG stock in 2026?
Our dual AI analysis gives FibroBiologics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FBLG's free cash flow?
FibroBiologics, Inc.'s operating cash flow is $-16.4M, with capital expenditures of $262.0K.
How does FBLG compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -302.9% (avg: 15%), current ratio 3.61 (avg: 2).